Aqueous extract of Salvia miltiorrhiza Bunge reduces blood pressure through inhibiting oxidative stress, inflammation and fibrosis of adventitia in primary hypertension

Ruoyu Wu, Yongjie Zhou, Hongjun Xu, Wei Zhao, Luyang Zhou, Yilin Zhao, Qingzhuo Cui, Junda Ning, Hongxu Chen, Shengjun AnFrontiers in Pharmacology 2023 · DOI

Abstract

Hypertension is a primary driver of global cardiovascular mortality. While conventional treatments like ACE inhibitors are effective, their side effects necessitate the exploration of alternative therapies. This study investigates the antihypertensive potential of SABP—a combination of aqueous metabolites from Salvia miltiorrhiza Bunge—focusing on its impact on the vascular adventitia. Using Spontaneously Hypertensive Rats (SHRs) and primary adventitial fibroblast cultures, researchers demonstrated that SABP significantly reduces blood pressure. The mechanism involves the inhibition of oxidative stress, inflammation, and fibrosis through the ROS/TLR4/NF-κB and TGFβ/Smad3 signaling pathways. These findings highlight SABP as a promising candidate for treating vascular remodeling in hypertension.

Introduction: Shifting Focus to the Vascular Adventitia

Traditional hypertension research often emphasizes the inner layers of blood vessels, namely the endothelium and media. However, recent evidence suggests the vascular adventitia—the outermost layer—plays a critical role in disease progression. In hypertensive states, adventitial fibroblasts (AFs) transform into myofibroblasts, initiating a cycle of inflammation and fibrosis that increases arterial stiffness.

The traditional Chinese herb Salvia miltiorrhiza Bunge (Danshen), from which the SABP extract is derived.

This study explores whether SABP, an optimized blend of hydrophilic metabolites (DSS, Sal-A, Sal-B, and PAL) from the herb Salvia miltiorrhiza (Danshen), can break this cycle and restore vascular health.

Methodology

The research utilized a dual-track experimental design:

  1. In Vivo Model: Spontaneously Hypertensive Rats (SHRs) were treated with daily intraperitoneal injections of SABP or perindopril (the positive control) for eight weeks. Blood pressure was monitored weekly via the tail-cuff method.
  2. In Vitro Model: Primary adventitial fibroblasts were isolated from the thoracic aortas of SHRs and healthy Wistar-Kyoto (WKY) rats to observe cellular responses to SABP treatment.

Advanced imaging and molecular techniques, including Transmission Electron Microscopy (TEM), Western Blotting, and CCK-8 assays, were used to evaluate structural damage and protein expression related to oxidative stress and fibrosis.

Key Findings

Blood Pressure and Structural Recovery

SABP treatment led to a significant reduction in blood pressure. After 6 weeks of treatment, systolic blood pressure (SBP) decreased by approximately 24.9 mmHg and diastolic blood pressure (DBP) by 21.5 mmHg. These results were comparable to the efficacy of the pharmaceutical control, perindopril.

The thoracic aorta was the primary focus for observing vascular remodeling and the effects of SABP treatment in hypertensive rats.

Microscopic analysis via TEM revealed that SABP protected the cellular architecture of the aorta, reducing mitochondrial cristae breakage and decreasing the thickness of the adventitia relative to the total vessel wall.

Molecular Mechanisms of Action

The study identified two primary pathways through which SABP exerts its protective effects:

  • Anti-Inflammatory and Antioxidant: SABP inhibited the ROS/TLR4/NF-κB signaling cascade, leading to a reduction in oxidative stress markers (NOX1, NOX2, NOX4) and inflammatory cytokines like IL-6.
  • Anti-Fibrotic: By suppressing the TGFβ/Smad3 pathway, SABP prevented the transformation of fibroblasts into myofibroblasts, thereby reducing the deposition of excess collagen (Collagen-I) and connective tissue growth factor (CTGF).

Discussion and Future Directions

The results suggest that the adventitia is a viable therapeutic target for hypertension. SABP's multi-pathway approach—targeting both inflammation and fibrosis—offers a comprehensive strategy for managing vascular remodeling.

While promising, the study notes limitations. The focus on the thoracic aorta should be expanded to smaller resistance vessels in future research. Additionally, the transition from intraperitoneal injection to oral delivery must be evaluated for clinical feasibility. Nonetheless, SABP represents a potent natural alternative for ameliorating the structural and functional damage associated with chronic hypertension.

Summary updated

Abstract

<b>Background:</b> Hypertension is a major risk factor for cardiovascular diseases and the leading cause of mortality worldwide. Despite the availability of antihypertensive drugs, alternative treatments are needed due to the adverse events associated with their use. Previous studies have shown that SABP, a combination of aqueous active metabolites of <i>Salvia Miltiorrhiza Bunge</i> DSS, Sal-A, Sal-B and PAL, has a significant antihypertensive effect. However, the underlying mechanisms remain unknown. <b>Objective:</b> This study aimed to determine the effects of SABP on vascular inflammation, oxidative stress, and vascular remodeling in spontaneously hypertensive rats (SHRs). Additionally, the response of adventitial fibroblasts in SHRs to SABP treatment was also studied, including their proliferation, differentiation, and migration. <b>Methods:</b> SABP or perindopril (positive control) were administered intraperitoneally to SHRs, and systolic blood pressure was measured using a tail-cuff approach. The effects of SABP on oxidative stress, inflammation, and vascular remodeling were investigated by transmission electron microscopy, histochemical staining, and Western blot. Adventitial fibroblasts were isolated and cultured from the adventitia of thoracic aorta in SHR and WKY rats. CCK8 assay, wound healing method and immunostaining were used to observe the effect of SABP on fibroblasts proliferation, migration and transformation into myofibroblasts. Moreover, Western blot analysis was also performed to detect the proteins related to oxidative stress, inflammation and fibrosis in adventitial fibroblasts. <b>Results:</b> SHRs displayed higher blood pressure with significant vascular remodeling compared to WKY rats. The thoracic aorta and adventitial fibroblasts of SHRs exhibited significant oxidative stress, inflammation and fibrosis. SABP treatment repressed oxidative stress, inflammatory reaction and vascular remodeling of thoracic aorta in SHR through the ROS/TLR4/NF-κB signaling pathway, and inhibited fibrosis of thoracic aorta. Additionally, SABP inhibited the proliferation and migration of adventitial fibroblasts and their transformation to myofibroblasts <i>in vitro</i> through the TGFβ/Smad3 signaling pathway. <b>Conclusion:</b> These findings suggest that SABP have potential as an alternative treatment for hypertension by ameliorating oxidative stress, inflammation and fibrosis. Further research is needed to fully understand the mechanisms underlying the effects of SABP.
BibTeX
@inproceedings{wu2023aqueous,
  author = {Ruoyu Wu and Yongjie Zhou and Hongjun Xu and Wei Zhao and Luyang Zhou and Yilin Zhao and Qingzhuo Cui and Junda Ning and Hongxu Chen and Shengjun An},
  title = {{Aqueous extract of Salvia miltiorrhiza Bunge reduces blood pressure through inhibiting oxidative stress, inflammation and fibrosis of adventitia in primary hypertension}},
  booktitle = {Frontiers in Pharmacology},
  year = {2023},
  doi = {10.3389/fphar.2023.1093669},
}
Figure